Stemline Therapeutics postpones IPO


Shutterstock photo

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, postponed its IPO on Tuesday. The New York, NY-based company had been planning to raise $42 million at a price range of $11 to $13. RBC Capital Markets, Oppenheimer & Co. were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: STML

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by